Category - Developments

Developments

Anixa Biosciences, Moffitt Cancer Center complete viral vector reformulation for CAR-T program

Anixa Biosciences (NASDAQ: ANIX) and the Moffitt Cancer Center, Anixa’s development partner, completed and validated the reformulation of the viral vector necessary for its CAR-T program. The purpose of the...

February 12, 2020

Developments

Bee Vectoring completes successful registration trials for commercialization in Mexico

Bee Vectoring Technologies International (TSXV:BEE; OTCQB:BEVVF) completed three official registration trials of its Clonostachys rosea CR-7 biological fungicide on commercial strawberry and tomato crops in Mexico...

February 12, 2020

Developments

PAVmed subsidiary gets breakthrough device designation for esophageal DNA test

PAVmed’s (NASDAQ:PAVM) subsidiary, Lucid Diagnostics, received FDA breakthrough device designation for its EsoGuard esophageal DNA test. The EsoGuard test, which is performed on esophageal samples collected using...

February 11, 2020

Developments

PhaseBio Pharma granted EMA PRIME designation for antiplatelet drug

PhaseBio Pharmaceuticals (NASDAQ:PHAS) received the EMA’s priority medicines, or PRIME, designation for PB2452, a drug designed to reverse the effects of antiplatelet drug, ticagrelor. Ticagrelor is administered...

February 11, 2020

Developments

OncoSec closes cash infusion and ownership stake with China Grand Pharma group

Shareholders of OncoSec Medical (NASDAQ:ONCS) approved a strategic investment and partnership with a unit of China Grand Pharmaceutical and Healthcare Holdings and its U.S. affiliate, Sirtex Medical US Holdings. Under...

February 11, 2020

Developments

Myovant reports 88% one-year response rate in Phase 3 relugolix extension study

Myovant Sciences (NASDAQ:MYOV) reported that its Phase 3 extension study of once-daily relugolix, in combination with estradiol and norethindrone acetate, achieved a one-year 88% response rate in women with uterine...

February 10, 2020

Developments

vTv Therapeutics’ Phase 2 diabetes trial meets primary objective

vTv Therapeutics’ (NASDAQ:VTVT) Phase 2 trial of TTP399 in Type 1 diabetes (T1D) patients met its primary objective by demonstrating statistically significant improvements in HbA1c compared to placebo. The company...

February 10, 2020

Developments

Catalyst Biosciences reports positive Phase 2b data from hemophilia trial

Catalyst Biosciences (NASDAQ:CBIO) reported positive results from its Phase 2b trial of DalcA, a subcutaneously administered Factor IX (FIX) therapy for the treatment of hemophilia B. The study was designed to evaluate...

February 7, 2020

Developments

Soricimed reports first cohort completion in Phase 1b trial of SOR-C13

Closely-held Soricimed Biopharma reported that the MD Anderson Cancer Center completed the first cohort in its investigator-initiated trial of Soricimed’s SOR-C13. The trial, launched in September 2019, is building on...

February 7, 2020

Developments

FDA clears Kleo Pharma IND for multiple myeloma study

Closely-held Kleo Pharmaceuticals received FDA clearance of its IND to initiate a safety and tolerability clinical study, combining its KP1237, a CD38-targeting antibody recruiting molecule, with patients’ own...

February 6, 2020

Category - Developments

Subscribe